Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Pecs II Block | 80 patients scheduled for open biceps tenodesis Bupivacaine 20mL 0.5%: Interscalene nerve block with 20 mL 0.5% bupivacaine. Bupivacaine 20mL 0.25%: Pecs II fascial plane block with 20 mL 0.25% bupivacaine. | 0 | None | 0 | 80 | 0 | 80 | View |
| Surgical Infiltration | 80 patients scheduled for open biceps tenodesis Bupivacaine 20mL 0.5%: Interscalene nerve block with 20 mL 0.5% bupivacaine. Bupivacaine up to 15mL 0.25%: Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL. | 0 | None | 0 | 80 | 0 | 80 | View |